PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
77.26
-0.59 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
77.15
-0.10 (-0.14%)
After-hours: Dec 5, 2025, 7:22 PM EST
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $211.01M in the quarter ending September 30, 2025, with 7.23% growth. This brings the company's revenue in the last twelve months to $1.78B, up 97.54% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.78B
Revenue Growth
+97.54%
P/S Ratio
3.40
Revenue / Employee
$1,894,728
Employees
939
Market Cap
6.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PTCT News
- 1 day ago - PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 days ago - PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - The Motley Fool
- 3 days ago - PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript - Seeking Alpha
- 3 days ago - Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - The Motley Fool
- 4 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 days ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire
- 6 days ago - A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Motley Fool
- 11 days ago - Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 - PRNewsWire